Robert W. Holloway, MD
Medical Director (Gyn Onc), Gynecologic Oncologist
Cancer
Overview
Dr. Robert W. Holloway, MD is a board-certified gynecology oncologist in Orlando. Dr. Holloway joined the Florida Hospital Cancer Institute in 1994, and serves as the medical director of the Gynecologic Oncology Program. A graduate of Vanderbilt University School of Medicine, Dr. Holloway completed his OB/GYN residency at the University of Alabama at Birmingham and his fellowship in gynecologic oncology at Georgetown University in Washington, DC. Dr. Holloway is a Fellow of the American College of Surgeons. Additionally, Dr. Holloway is the principal investigator for several clinical trials and lectures regularly both nationally and internationally. His major research interests are robotic surgery and novel ovarian cancer therapies. Surgeons from around the world routinely attend his advanced training programs in robotic surgery.
Articles
Corrigendum to "A phase 1b study of intraperitoneal oncolytic viral immunotherapy in platinum-resistant or refractory ovarian cancer" [Gynecologic Oncology 163 (2021) 481-489].
Gynecologic oncology
2022
Multidisciplinary approach to pelvic leiomyomatosis with intracaval and intracardiac extension: A case report and review of the literature
GYNECOLOGIC ONCOLOGY REPORTS
2022
OVERALL SURVIVAL RESULTS FROM ARIEL3: A PHASE 3 RANDOMIZED, DOUBLE-BLIND STUDY OF RUCAPARIB VS PLACEBO FOLLOWING RESPONSE TO PLATINUM-BASED CHEMOTHERAPY FOR RECURRENT OVARIAN CARCINOMA
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
2022
MALIGNANT PERITONEAL CYTOLOGIC CONTAMINATION WITH ROBOTIC HYSTERECTOMY FOR ENDOMETRIAL CANCER
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
2022
A PHASE I/II STUDY EVALUATING INTRAPERITONEAL GEN-1 IN COMBINATION WITH NEOADJUVANT CHEMOTHERAPY IN PATIENTS NEWLY DIAGNOSED WITH ADVANCED EPITHELIAL OVARIAN CANCER
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
2022
PHASE 3 STUDY OF EFFICACY & SAFETY OF OLVI-VEC AND PLATINUM-DOUBLET plus BEVACIZUMAB COMPARED TO PLATINUM-DOUBLET plus BEVACIZUMAB IN PLATINUM-RESISTANT/REFRACTORY OVARIAN CANCER (ONPRIME; GOG-3076) [NCT05281471]
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
2022
Clinical and molecular characteristics of ARIEL3 patients who derived exceptional benefit from rucaparib maintenance treatment for high-grade ovarian carcinoma
Gynecologic oncology
2022
The added value of SLN mapping with indocyanine green in low- and intermediate-risk endometrial cancer management: a systematic review and meta-analysis
JOURNAL OF GYNECOLOGIC ONCOLOGY
2022
Immunotherapy in the Treatment of Platinum-Resistant Ovarian Cancer: Current Perspectives
ONCOTARGETS AND THERAPY
2022
The gut microbiome and cancer immunotherapeutics: A review of emerging data and implications for future gynecologic cancer research
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
2021
Education & Training
Education
Vanderbilt University Medical Center
Residency
University of Alabama Birmingham
Fellowship
Georgetown University Hospital
Specialty
Gynecology Oncology
Board Certifications
American Board of Obstetrics & Gynecology